Carbamazepine: here's the fair price
This is what US pharmacies pay, on average, for carbamazepine. Use it to spot a fair cash price, and feel good about asking for one.
Carbamazepine 200 Mg Tablet
A fair cash price is usually this cost plus a dispensing fee. If your quote is many times higher, ask about a generic, another pharmacy, or a cash discount.
Ask for generic Carbamazepine 200 Mg Tablet. Pharmacies pay about $3.58 for 30. Ask your pharmacy for its cash price and compare it with your copay. A fair cash price is close to this cost plus a dispensing fee.
Source: CMS NADAC as of 2026-11-04. Ask your prescriber or pharmacist whether a generic is right for you.
Source: CMS NADAC weekly file as of 2026-11-04. Median across NDCs with the same description. Public domain.
Your ZIP and location stay in your browser. We never store them.
Every strength and form
| Product | Pharmacy cost | 30 count | Effective |
|---|---|---|---|
| CARBAMAZEPINE 100 MG/5 ML SUSPGeneric | $0.09 per mL | n/a | 10/21/2026 |
| CARBAMAZEPINE 200 MG TABLETGeneric | $0.12 per tablet or capsule | $3.58 | 10/21/2026 |
| CARBAMAZEPINE ER 100 MG TABLETGeneric | $0.20 per tablet or capsule | $5.98 | 10/21/2026 |
| CARBAMAZEPINE 100 MG TAB CHEWGeneric | $0.23 per tablet or capsule | $6.82 | 10/21/2026 |
| CARBAMAZEPINE ER 200 MG TABLETGeneric | $0.38 per tablet or capsule | $11.38 | 10/21/2026 |
| CARBAMAZEPINE ER 400 MG TABLETGeneric | $0.71 per tablet or capsule | $21.25 | 10/21/2026 |
| CARBAMAZEPINE ER 200 MG CAPGeneric | $1.03 per tablet or capsule | $30.98 | 10/21/2026 |
| CARBAMAZEPINE ER 100 MG CAPGeneric | $1.09 per tablet or capsule | $32.80 | 10/21/2026 |
| CARBAMAZEPINE ER 300 MG CAPGeneric | $1.13 per tablet or capsule | $33.95 | 10/21/2026 |
| CARBAMAZEPINE 200 MG TAB CHEWGeneric | $1.19 per tablet or capsule | $35.71 | 10/21/2026 |
Source: CMS NADAC, as of 2026-11-04. National average acquisition cost, not a retail quote.
Label basics
What it is used for (FDA label)
INDICATIONS AND USAGE Epilepsy Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: 1. Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. 2. Generalized tonic-clonic seizures (grand mal). 3. Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS , General). Trigeminal...
Common side effects (FDA label)
ADVERSE REACTIONS If adverse reactions are of such severity that the drug must be discontinued, the physician must be aware that abrupt discontinuation of any anticonvulsant drug in a responsive epileptic patient may lead to seizures or even status epilepticus with its life-threatening hazards. The most severe adverse reactions have been observed in the hemopoietic system and skin (see BOXED WARNING), the liver, and the cardiovascular system. The most frequently observed adverse reactions, particularly during the initial phases of therapy, are dizziness, drowsiness, unsteadiness, nausea, and...
Drug interactions (from the label)
Drug Interactions There has been a report of a patient who passed an orange rubbery precipitate in his stool the day after ingesting carbamazepine suspension immediately followed by Thorazine solution. Subsequent testing has shown that mixing carbamazepine suspension and chlorpromazine solution (both generic and brand name) as well as carbamazepine suspension and liquid Mellaril, resulted in the occurrence of this precipitate. Because the extent to which this occurs with other liquid medications is not known, carbamazepine suspension should not be administered simultaneously with other liquid medicinal agents or diluents (see DOSAGE AND ADMINISTRATION). Clinically meaningful drug...
Warnings (from the label)
WARNINGS Serious Dermatologic Reactions Serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS), have been reported with carbamazepine treatment. The risk of these events is estimated to be about 1 to 6 per 10,000 new users in countries with mainly Caucasian populations. However, the risk in some Asian countries is estimated to be about 10 times higher. Carbamazepine should be discontinued at the first sign of a rash, unless the rash is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed and alternative therapy should be considered. SJS/TEN and HLA-B*1502 Allele...
Source: FDA drug label via openFDA, label effective 2025-02-18. Full label on DailyMed. Excerpts are verbatim and truncated. Read the full label and ask your pharmacist.